All In Biotech

NDA 205422 · Otsuka

Rexulti

Brexpiprazole · Oral · Atypical Antipsychotic

Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jul 10, 2015

Approved uses

7

Original approval plus efficacy supplements

Registered trials

81

50 Phase 3, 7 recruiting

FAERS reports

16,890

7,192 serious, 1,179 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease. ( 5.1 ) Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. Safety and effectiveness of REXULTI have not been established in pediatric patients with...

What it is approved for

From the label in effect Jun 2, 2026.

REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease Limitations of Use: REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease [see Clinical Studies (14.3) ] . REXULTI is an atypical antipsychotic indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1 , 14.1 ) Treatment of schizophrenia in adults and pediatric patients ages 13 years and older ( 1 , 14.2 ) Treatment of agitation associated with dementia due to Alzheimer's disease ( 1 , 14.3 ) Limitations of Use : REXULTI is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease ( 1 )

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • REXULTI · BREXPIPRAZOLE 3MG · TABLET, ORAL · Prescription · TE AB
  • REXULTI · BREXPIPRAZOLE 1MG · TABLET, ORAL · Prescription · TE AB
  • REXULTI · BREXPIPRAZOLE 0.25MG · TABLET, ORAL · Prescription · TE AB
  • REXULTI · BREXPIPRAZOLE 4MG · TABLET, ORAL · Prescription · TE AB
  • REXULTI · BREXPIPRAZOLE 2MG · TABLET, ORAL · Prescription · TE AB
  • REXULTI · BREXPIPRAZOLE 0.5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Brexpiprazole" as an intervention, any sponsor and status, largest first.

All 81 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • weight increased1,712
  • product use in unapproved indication1,400
  • off label use1,172
  • drug ineffective984
  • akathisia880
  • tremor662
  • anxiety629
  • death603
  • tardive dyskinesia603
  • depression598
  • suicidal ideation595
  • product use issue516

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20131
2015229
20162,107
20171,551
20181,417
20191,701
20201,423
20211,433
20221,328
20231,446
20241,781
20251,372
20261,100

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rexulti (Brexpiprazole)

2024 spending

$861M

Beneficiaries

94,695

598,492 claims

Per beneficiary

$9,096

$49.56 per unit

View as table
YearSpending
2020$358,159,997
2021$403,387,369
2022$490,498,963
2023$630,013,840
2024$861,392,150

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 127 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.